RxDoctor Payments Data

Yuvraj Heir, MD

Neurology · The Woodlands, TXNPI 1588076665

Payments from drug & device makers

$21,949in general payments, 2019–2025

Across 1,153 payments — averaging $19.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • UCB, Inc.$2K
  • EMD Serono, Inc.$1K
  • Amgen$1K
  • Novartis$1K
  • AstraZeneca$1K
  • plus $12K from 54 others

What the payments were for

  • Speaking & faculty fees$1531%
  • Food & beverage$21,41898%
  • Education$3782%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)189$2,654
UCB, Inc.90$2,374
EMD Serono, Inc.67$1,288
Amgen49$1,054
Novartis78$1,013
AstraZeneca(2 entities)40$1,002
Eisai Inc.41$912
SK Life Science, Inc.37$800
Teva Pharmaceuticals USA, Inc.33$793
Pfizer31$778
Sanofi35$683
Lilly USA, LLC52$681
Biogen34$658
Acadia Pharmaceuticals Inc28$562
Takeda Pharmaceuticals U.S.A., Inc.20$485
Neurocrine Biosciences, Inc.23$481
Abbott16$456
Biohaven Pharmaceutical Holding Company Ltd.28$385
Johnson & Johnson(2 entities)16$329
Lundbeck LLC17$320
Argenx US, Inc.10$310
Otsuka America Pharmaceutical, Inc.16$284
Amneal Pharmaceuticals LLC18$280
Bristol Myers Squibb11$215
Biohaven Pharmaceuticals, Inc.17$197
TG Therapeutics, Inc.7$181
Avanir Pharmaceuticals, Inc.10$175
Grifols USA, LLC8$164
Acorda Therapeutics, Inc8$153
Boston Scientific4$152
Supernus Pharmaceuticals, Inc.10$139
MDD US Operations, LLC8$135
Averitas Pharma Inc.7$127
Jazz Pharmaceuticals Inc.5$126
Tanabe Pharma America, Inc.7$105
Neurelis, Inc.4$97
Akcea Therapeutics, Inc.3$92
CSL Behring6$92
Tersera Therapeutics LLC3$87
Collegium Pharmaceutical, Inc.4$74
Sumitomo Pharma America, Inc.8$67
Upsher-smith Laboratories LLC4$66
Kyowa Kirin, Inc.3$63
Livanova USA, Inc.2$63
Piramal Critical Care4$59
Assertio Therapeutics, Inc.4$54
GE HealthCare3$53
Impel Pharmaceuticals LLC2$46
Genentech USA, Inc.3$41
Zyla Life Sciences, Inc.2$40
Corium, LLC2$37
Sarepta Therapeutics, Inc.2$36
Medtronic2$36
Axsome Therapeutics, Inc.1$33
Catalyst Pharmaceuticals, Inc.1$29
Alnylam Pharmaceuticals Inc.1$28
Saluda Medical Americas, Inc.1$27
Merz Pharmaceuticals, LLC1$27
Arbor Pharmaceuticals, Inc.2$26
ZOLL Respicardia, Inc.1$26

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,949 in reported general payments places this provider in the 75th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$287,703
Medicare patients
710
Services billed
11,294

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate32$267,145
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5034$222,627
Gamunex-CImmune Globul G/Gly/Iga Avg 4613$123,959
BriviactBrivaracetam12$33,115
XcopriCenobamate17$22,416
Nurtec OdtRimegepant Sulfate11$16,937
Emgality PenGalcanezumab-Gnlm17$11,452
Aimovig AutoinjectorErenumab-Aooe15$11,359
Mycophenolate Mofetil11$5,455
Lacosamide41$4,831
Carbidopa-LevodopaCarbidopa/Levodopa102$4,297
Pregabalin133$4,168
Carbamazepine ErCarbamazepine19$3,659
Levetiracetam74$3,297
Donepezil Hcl262$3,237

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$481$267,14532 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$485$222,62734 claims
Grifols USA, LLCGamunex-C$164$123,95913 claims
UCB, Inc.Briviact$2,374$33,11512 claims
SK Life Science, Inc.Xcopri$800$22,41617 claims
PfizerNurtec Odt$778$16,93711 claims
Amneal Pharmaceuticals LLCMycophenolate Mofetil, Pyridostigmine Bromide$280$7,72236 claims
Upsher-smith Laboratories LLCTopiramate$66$76765 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,246 neurology providers in Texas.

Other neurology in The Woodlands

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →